Aricept

CLININCAL GUIDANCE ON DONEPEZIL FOR GENERAL PRACTITIONERS 1.0 1.1 Introduction Donepezil hydrochloride Arkcept ; has recently been licensed in the UK for the treatment of mild to moderate Alzheimer's disease. Currently there is no published evidence of its beneficial effects on multi-infarct dementia. Donepezil provides symptomatic treatment. It acts by inhibiting the enzyme responsible for metabolising acetylcholine, thereby enhancing neurotransmitter levels. As the cholinergic neurones degenerate, the benefits derived from treatment are likely to reduce over time. To date two trials have been published in full. There is some evidence that donepezil gives a modest, short-term improvement in cognitive function but it does not appear to alter the underlying disease process. Its maximum benefits are derived early in the treatment and cognitive changes are probably equivalent to approximately a 3-6 month delay in disease progression. It is generally well tolerated but as acetylcholine is found in cells throughout the body side effects may occur. The Drug and Therapeutics Bulletin of October 1997 highlights that the clinical significance of these changes for patients and their carers is uncertain and, on the basis of the published evidence, the Bulletin does not recommend the use of Donepezil. However, since this was written the journal Neurology, in January 1998, published an article highlighting the benefits of treatment with Donepezil. Doctors should, therefore, carefully consider all available evidence prior to prescribing this drug. Patient Selection When treatment is being considered, the early, accurate diagnosis of patients with mild to moderate Alzheimer's disease is essential. Therefore, where there is a suspicion of an acquired disturbance of memory, cognition, language and personality in clear consciousness it is recommended that the patient should be referred for specialist evaluation prior to commencement of treatment. Consultants in neurology, psychiatry of old age and geriatric medicine are best placed to establish the accurate diagnosis of mild to moderate dementia of Alzheimer's disease. A patient with a Mini-Mental State Examination giving rise to a score of 10-26 would fulfil the grading criteria associated with mild to moderate dementia. Patients should be referred in the usual way unless there is a high index of suspicion of major pathology requiring urgent treatment. Those patients who are under the age of 65 years and who have a possible diagnosis of dementia should be referred to a consultant neurologist or other local specialist with expertise. There may be a requirement for referral to a specialist centre for screening for familial dementia. A detailed medical and drug history needs to be included in the referral in order to ensure there is no interaction between the proposed treatment and other drug treatments or conditions such as cardiovascular, gastrointestinal, pulmonary, genitourinary and neurological conditions. References: 1. Agicept SmPC 2. Aricepr Evess SmPC 3. Rivastigmine SmPC 4. Galantamine SmPC 5. Galantamine XL SmPC 6. Memantine SmPC 7. Data on File Studies 015, 016 and 017 Eisai Ltd, Pfizer Ltd ; Date of preparation: January 2007 AR1016-ARI984 12-06. 3.2. Changes in exopeptidase activities after feeding Females were given a blood, protein or amino acid meal. Enzymatic activities were measured in crude midgut extracts at different times after feeding. Midgut of unfed females contained relatively high aminopeptid.
The results of a clinical trial published in the journal of the american medical association showed alzheimer' s patients taking namenda in combination with aricept experienced a slower rate of decline in thinking, function and behavior compared to those taking aricept alone * the study found that combination therapy with namenda + aricept may 3, 13-15 : improve and maintain thinking help maintain the ability to perform activities of daily living such as grooming, finding belongings and conversing significantly improve behavior delay the onset of negative behavior such as agitation, aggression, and irritability in asymptomatic people by treating the symptoms of alzheimer' s disease, namenda, in combination with aricept, may do more to treat the symptoms of the disease and allow people with alzheimer' s to recognize and interact with family and friends longer and may help make life more manageable for everyone involved. Knowing that i have a family history of depression including suicide ; , i finally went to the doctor and got on an ssri when i was barely able to function at work, and barely able to take care of my child the rest of the time. Never had any pregnancy scare, but, the hormones were messin me approach up and trileptal. ABILIFY excluding Discmelt & solution ; ACCU-CHEK ACTIVE KIT ACCU-CHEK ACTIVE test strips ACCU-CHEK ADVANTAGE KIT ACCU-CHEK ADVANTAGE test strips ACCU-CHEK AVIVA KIT ACCU-CHEK AVIVA test strips ACCU-CHEK COMFORT CURVE test strips ACCU-CHEK COMPACT KIT ACCU-CHEK COMPACT test strips ACCU-CHEK COMPLETE KIT acetaminophen w codeine acetazolamide ACTIVELLA ACTONEL, with calcium ACTOPLUS MET ACTOS acyclovir ADDERALL XR * ADVAIR DISKUS, HFA ADVICOR [ST] AGGRENOX albuterol ALLEGRA-D * excluding 24 hours ; ALOCRIL ALOMIDE ALORA ALPHAGAN P ALTACE [ST] aluminum chloride amantadine aminophylline amitriptyline amlodipine besylate ammonium lactate amox tr potassium clavulanate amoxicillin ANALPRAM-HC * 1% cream, 2.5% lotion ; ANDRODERM ANDROGEL * antipyrine w benzocaine apri aranelle ARANESP [INJ] [PA] ARICEPT ASACOL ASTELIN atenolol, -chlorthalidone AUGMENTIN XR AVANDAMET AVANDARYL AVANDIA AVELOX aviane AVODART AXID solution only azathioprine azithromycin COSOPT COZAAR [ST] CREON CRESTOR [ST] cromolyn sodium cryselle cyclobenzaprine hcl cyclosporine, modified CYMBALTA [SNRI] [ST].

If this medication is used for seizures, do not stop taking it without consulting your doctor and antabuse.
Even when taken in very high doses, it does not appear to cause any toxic effects.

All four of the cholinesterase inhibitors have the same FDA approved indication for Alzheimer's disease. A review of the pharmacokinetic properties of each agent shows donepezil Adicept ; kinetics are not affected by food, and rivastigmine Exelon ; is the single agent not metabolized by the cytochrome P450 enzyme system, resulting in less potential for drug interaction. Above all, use of tacrine Cognex ; is associated with high rates of liver transaminase level elevations, making it the cholinesterase inhibitor at a significant disadvantage due to adverse events. With regards to dosing, donepezil is the only cholinesterase inhibitor dosed once daily with no dosing titration, and is the only drug studied in combination with memantine Namenda ; . In addition, clinical data from trials listed above suggest donepezil is better tolerated than rivastigmine or galantamine. However, only galantamine and rivastigmine are available in an oral liquid formulation. Efficacy data on cognitive function from trials comparing the cholinesterase inhibitors is mixed. More head-to-head studies are needed between these agents to fully evaluate their efficacy. Currently, the agents in this class excluding tacrine ; remain comparable in efficacy, and important in the treatment of Alzheimer's disease. A significant amount of literature supports use of the cholinesterase inhibitors as first-line agents for mild-moderate AD. However, as there are no drugs commonly used for their effectiveness in moderate-to-severe AD, the small benefit offered by memantine may be beneficial for some patients who have tried and failed cholinesterase inhibitors or whose cognitive disease continues to progress. Until more efficacy data becomes available, memantine should be reserved for those patients who have not responded to other first-line agents cholinesterase inhibitors ; for AD. Therefore, donepezil, rivastigmine, and galantamine offer significant clinical advantage in general use but are comparable to each other. Additionally, tacrine Cognex ; possesses an extensive adverse effect profile and lariam.

VIENNA, Oct. 29 PRNewswire-FirstCall -- At the 6th Congress of the European Federation of Neurological Societies in Vienna, Shire Pharmaceuticals Group plc Nasdaq: SHPGY; LSE: SHP; TSE: SHQ ; has today presented data with Janssen-Cilag Ltd which shows that over one year, Reminyl galantamine ; has a superior treatment profile compared to donepezil Aricept ; when treating patients with Alzheimer's Disease AD ; . This is the first one-year head to head study of the two drugs. Results of the long-term, rater-blinded, randomized study conducted in the UK show that in two assessments of AD patients, those treated with Reminyl had statistically superior scores on measures of cognition and attention compared to those treated with donepezil. Reminyl was shown to significantly improve a patient's attention within six weeks of commencing treatment, using a validated computerized test for assessing cognitive performance. These computerized assessments, by the independent company, Cognitive Drug Research CDR ; , measure a patient's reaction times and showed that patients taking Reminyl significantly improved their choice reaction times CRT ; compared to donepezil patients after only six weeks of treatment. At 52 weeks, Reminyl patients' CRT had been maintained at baseline levels. Patients treated with donepezil had no significant changes in CRT throughout the study. The improvements in attention, as measured by the computerized tests for patients taking Reminyl, are thought to be due to its action on nicotinic receptors. "Reminyl is different to other acetylcholinesterase inhibitors AChEIs ; because it increases the levels of acetylcholine by two separate mechanisms. As well as inhibiting acetylcholinesterase, it has also been shown to enhance activity of nicotinic receptors, " says Dr Roger Bullock of the Kingshill Research Centre, Swindon. "Nicotinic receptors are known to be important in maintaining attention and concentration. These results demonstrate the importance of Reminyl's dual mode of action." Dr Bullock says: "Being able to improve a patient's ability to take part in family events by increasing their attention and concentration adds an important, but often neglected quality to the lives of both patients and their carers." Patients treated with Reminyl were also more likely to improve or maintain their level of dementia throughout the study compared with those patients taking donepezil, as measured by the MMSE Mini Mental State Examination ; assessment scale for AD. The MMSE, which measures cognition by testing functions such as memory, orientation and language, is the assessment scale recommended by the National Institute for Clinical Excellence NICE ; and the one that most clinicians use on a daily basis. At 13 and 26 weeks, the MMSE score for Reminyl was significantly improved compared with the baseline assessment. At 52 weeks, patients had been maintained at their baseline score. Patients treated with donepezil only saw significant improvement above baseline at the 13 week time point. At 26 weeks, their score had returned to baseline values, whilst after 52 weeks, patients treated with donepezil were statistically below their baseline scores. For those patients less severely affected by AD, those who fitted the NICE criteria for treatment with AD drugs with a baseline MMSE score of 12-18 points ; , the results were even more favorable for Reminyl. Reminyl was significantly superior to donepezil at all time points measured throughout the 52 weeks study. Reminyl was comparable to donepezil in terms of safety and tolerability, with similar discontinuation rates during the study and similar numbers of patients continuing on therapy after the end of the study. The primary end point for the study was the Bristol Activities of Daily Living BrADL ; rating scale, which measures a patient's ability to function. Patients treated with Reminyl and donepezil performed equally well in this assessment. This study confirms that Reminyl treated patients demonstrate an early improvement in attention and sustained cognitive benefits. Reference: 1. Truyen L. et al. Poster presentation at 6th Congress of The European Federation of Neurological Societies, Vienna, Austria, 29 October. Downs notes a modest elevation of GS side effects compared to other in its class. Dr. Downs prefers Donepezil as the preferred agent. The rationale for the use of Cholinesterase Inhibitors in Alzheimer's Disease is based on well-established evidence of severe loss of cholinergic neurons in this degenerative disease and the association between cholinergic pathways and memory disorder. Tacrine has modest benefits in a minority of patients with a poor toxicity profile. Donepezil produced modest improvements with mild and moderate Alzheimer's dementia. Donepezil is chemically distinct within this group. Rivastigmine is equally effective with Donepezil in a 12-week open label highly biased study, but also had more side effects specifically GI in nature. The activation effect was noted and it is beneficial in patients with cognitive depression, many of which are elderly. The Veterans formulary currently has Donepezil, Galantamine and Tacrine available. Jeffrey Demain noted that Aricept was dosed once daily and was not impacted by food, which may be important when talking about the complications with delivering medications. Kelly Conright said Aricept showed some efficacy in mild cognitive impairment. Patients with mild cognitive impairment and no official caregivers do not need a twice-daily medication. The tolerability, once of day dosing and the long tract record of Aricept is important. George Stransky did not feel Tacrine should be included on the preferred drug list due to its toxicity. In response to Thomas Hunt, Terry Babb said they currently did not have a way to evaluate pharmacological economic information on the Committee. THOMAS HUNT MOVED TO PLACE ARICEPT ON THE PREFERRED DRUG LIST. SECONDED BY JEFFREY DEMAIN. CHAIRMAN BRODSKY CALLED FOR DISCUSSION ON THE MOTION. George Stransky noted that Aricept accounted for about 80% of the Alaskan market. CHAIRMAN BRODSKY CALLED FOR A VOTE ON THE MOTION. MOTION PASSED UNANIMOUSLY. X. COPD ANTICHOLINERGICS. About results results 1 - 20 of for aricept hide this set goodtree as your homepage: click here to do it automatically use goodtree for your everyday searching - get the firefox search bar plugin set goodtree as your homepage - click here to learn how sponsored links official site actonel risedronate sodium tablets ; learn details of free trial offer. More information on buttock augmentation and a cosmetic surgeon in your area is just a click away.

Patient with Alzheimer's disease approach , 000 per year, a prescription for Aricept costs approximately per day , 700 per year ; . Five Canadian provinces - Quebec, Ontario, Manitoba, Saskatchewan, and Alberta - currently offer reimbursement to patients who use Aricept and who meet selected criteria. In June 1999, Ontario became the first province to offer reimbursement for Aricept under the Ontario Drug Benefit Program. Manitoba Heath announced that it too would add Aricept to its benefit list, and Alberta placed Aricept on the Alberta Health and Welfare Drug Benefit List AHWDBL ; on December 1, 1999. When Alberta added Aricept to the AHWDBL, 1, 100 Albertans paid for the medication, and an additional 6, 000 Albertans who were not taking the Aricept could benefit from it. Quebec and Saskatchewan added Aricept to their individual drug reimbursement programs in 2000. Saskatchewan estimates that 1 in 5 patients with Alzheimer's disease will benefit from using Aricept. To qualify for reimbursement, a patient must have a diagnosis of mild-to-moderate probable Alzheimer's disease Alzheimer's cannot be definitively diagnosed until after death, at autopsy, therefore all diagnoses are referred to as probable ; . Cognitive and functional evaluations may also be used to establish eligibility for reimbursement. The patient's cognitive and functional abilities are determined with the Mini-Mental State.

Aricept without prescription